1.Ellis, KL, Boffa, MB, Sahebkar, A, et al. (2017) The renaissance of lipoprotein(a): brave new world for preventive cardiology? Prog Lipid Res 68, 57–82.
2.Nordestgaard, BG, Chapman, MJ, Ray, K, et al. (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31, 2844–2853.
3.Kronenberg, F & Utermann, G (2013) Lipoprotein(a): resurrected by genetics. J Intern Med 273, 6–30.
4.Berk, KA, Yahya, R, Verhoeven, AJM, et al. (2017) Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetes. Diabetologia 60, 989–997.
5.Faghihnia, N, Tsimikas, S, Miller, ER, et al. (2010) Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res 51, 3324–3330.
6.Berglund, L, Lefevre, M, Ginsberg, HN, et al. (2007) Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr 86, 1611–1620.
7.Ginsberg, HN, Kris-Etherton, P, Dennis, B, et al. (1998) Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol 18, 441–449.
8.Silaste, ML, Rantala, M, Alfthan, G, et al. (2004) Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol 24, 498–503.
9.Wang, DD & Hu, FB (2017) Dietary fat and risk of cardiovascular disease: recent controversies and advances. Annu Rev Nutr 37, 423–446.
10.Mozaffarian, D, Micha, R & Wallace, S (2010) Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 7, e1000252.
11.Hooper, L, Martin, N, Abdelhamid, A, et al. (2015) Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev, issue 6, Cd011737.
12.Chowdhury, R, Warnakula, S, Kunutsor, S, et al. (2014) Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 160, 398–406.
13.Ramsden, CE, Zamora, D, Majchrzak-Hong, S, et al. (2016) Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968–73). BMJ 353, i1246.
14.Sacks, FM, Lichtenstein, AH, Wu, JHY, et al. (2017) Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation 136, e1–e23.
15.Piepoli, MF, Hoes, AW, Agewall, S, et al. (2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37, 2315–2381.
16.Harris, WS, Poston, WC & Haddock, CK (2007) Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 193, 1–10.
17.Virtanen, JK, Wu, JHY, Voutilainen, S, et al. (2018) Serum n-6 polyunsaturated fatty acids and risk of death: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr 107, 427–435.
18.Marklund, M, Wu, JHY, Imamura, F, et al. (2019) Biomarkers of dietary omega-6 fatty acids and incident cardiovascular disease and mortality: an individual-level pooled analysis of 30 cohort studies. Circulation 139, 2422–2436
19.Ramsden, CE, Zamora, D, Leelarthaepin, B, et al. (2013) Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ 346, e8707.
20.Zhao, JV & Schooling, CM (2019) Effect of linoleic acid on ischemic heart disease and its risk factors: a Mendelian randomization study. BMC Med 17, 61.
21.Nordestgaard, BG, Chapman, MJ, Humphries, SE, et al. (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34, 3478–3490.
22.Mundal, L, Veierod, MB, Halvorsen, T, et al. (2016) Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994–2009, a registry study. Eur J Prev Cardiol 23, 1962–1969.
23.Alonso, R, Andres, E, Mata, N, et al. (2014) Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 63, 1982–1989.
24.Ulven, SM, Leder, L, Elind, E, et al. (2016) Exchanging a few commercial, regularly consumed food items with improved fat quality reduces total cholesterol and LDL-cholesterol: a double-blind, randomised controlled trial. Br J Nutr 116, 1383–1393.
25.Kawashima, A, Sugawara, S, Okita, M, et al. (2009) Plasma fatty acid composition, estimated desaturase activities, and intakes of energy and nutrient in Japanese men with abdominal obesity or metabolic syndrome. J Nutr Sci Vitaminol (Tokyo) 55, 400–406.
26.Carlsen, MH, Lillegaard, IT, Karlsen, A, et al. (2010) Evaluation of energy and dietary intake estimates from a food frequency questionnaire using independent energy expenditure measurement and weighed food records. Nutr J 9, 37.
27.Graham, I, Atar, D, Borch-Johnsen, K, et al. (2007) European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14, S1–113.
28.Russo, GL (2009) Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem Pharmacol 77, 937–946.
29.Hanna, VS & Hafez, EAA (2018) Synopsis of arachidonic acid metabolism: a review. J Adv Res 11, 23–32.
30.Hikita, H, Shigeta, T, Kimura, S, et al. (2015) Coronary artery disease severity and cardiovascular biomarkers in patients with peripheral artery disease. Int J Angiol 24, 278–282.
31.Schmocker, C, Kassner, U, Kiesler, S, et al. (2016) A lipidomic analysis approach in patients undergoing lipoprotein apheresis. Atherosclerosis 249, 30–35.
32.Schmocker, C, Kassner, U, Ostermann, AI, et al. (2017) Effect of different lipid apheresis methods on plasma polyunsaturated fatty acids. Atheroscler Suppl 30, 193–199.
33.Li, D, Ball, M, Bartlett, M, et al. (1999) Lipoprotein(a), essential fatty acid status and lipoprotein lipids in female Australian vegetarians. Clin Sci 97, 175–181.
34.Lee, JM, Lee, H, Kang, S, et al. (2016) Fatty acid desaturases, polyunsaturated fatty acid regulation, and biotechnological advances. Nutrients 8, 23.
35.Nakamura, MT & Nara, TY (2004) Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu Rev Nutr 24, 345–376.
36.Gencer, B, Kronenberg, F, Stroes, ES, et al. (2017) Lipoprotein(a): the revenant. Eur Heart J 38, 1553–1560.
37.Burgess, S, Ference, BA, Staley, JR, et al. (2018) Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol 3, 619–627.
38.Spector, AA (2001) Plasma free fatty acid and lipoproteins as sources of polyunsaturated fatty acid for the brain. J Mol Neurosci 16, 159–165; discussion 215–121.
39.Tsimikas, S, Tsironis, LD & Tselepis, AD (2007) New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 27, 2094–2099.
40.Ruuth, M, Nguyen, SD, Vihervaara, T, et al. (2018) Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. Eur Heart J 39, 2562–2573.
41.Zhao, A, Yu, J, Lew, JL, et al. (2004) Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA Cell Biol 23, 519–526.
42.Hoover-Plow, J & Huang, M (2013) Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metab Clin Exp 62, 479–491.
43.Hodson, L, Skeaff, CM & Fielding, BA (2008) Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res 47, 348–380.
44.Torvik, K, Narverud, I, Ottestad, I, et al. (2016) Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia. Atherosclerosis 252, 21–27.
45.Bogsrud, MP, Graesdal, A, Johansen, D, et al. (2019) LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia. J Clin Lipidol 13, 279–286.
46.Arroyo-Olivares, R, Alonso, R, Quintana-Navarro, G, et al. (2019) Adults with familial hypercholesterolaemia have healthier dietary and lifestyle habits compared with their non-affected relatives: the SAFEHEART study. Public Health Nutr 22, 1433–1443.